Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that drugs intended for the treatment of epilepsy and schizophrenia are often used for other diseases. Off-label use of central nervous system drugs can account for 25% to more than 80% of a drug's total sales, according to a new PhysicianForum report from Decision Resources entitled Off-Label Use of CNS Drugs.

(Photo: )

"For many central nervous system indications, off-label prescribing is quite significant. For example, the antiepileptic drugs Depakote and Neurontin were used last year between 40 - 80% of the time for off-label indications," said Christine Blazynski, Ph.D., director at Decision Resources.

Physician groups surveyed for this report revealed that a major factor in prescribing off-label drugs is the inability of labeled drugs to satisfy unmet clinical need. "For primary care physicians and neurologist, unmet clinical need is the most influential factor, followed by severity of symptoms," continued Dr. Blazynski. "However for psychiatrists, symptom severity has slightly more influence over unmet clinical need."

Off-Label Use of CNS Drugs includes surveys of 54 primary care physicians, 27 neurologists and 25 psychiatrists regarding their off-label drug prescribing habits in both neurological and psychiatric diseases. Their responses were compared in order to access similarities and differences between clinical, economic and scientific factors.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume-prescribing primary care physicians, specialists, and manage care representatives in the United States and Europe; analysis of events and responses to them; insight into prescribing patterns; and predictions for the pharmaceutical market based on the results.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 

Make Your Opinion Count - Click Here

Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

Web site: http:///

Parkinson's Disease Drug Market to Double by 2011

View Now